Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

BCS

Current Report · Items 2.02, 7.01, 9.01 · 8-K

REVIVA PHARMACEUTICALS HOLDINGS, INC.

RVPHOTCEQUITYCurrent

Results of Operations and Financial Condition · Regulation FD Disclosure

Item 2.02. Results of Operations and Financial Condition. Reviva Pharmaceuticals Holdings, Inc. (the “Company”) issued a press release on May 13, 2026 disclosing financial information and operating metrics for its fiscal quarter ended March 31, 2026 and discussing its business outlook.…

Filed May 13, 2026Accepted May 13, 2026, 4:41 PM EDTCIK 1742927Accession 0001437749-26-016760
Share

Company context

Current securities

Historical securities (4)

Recent company filings

  1. 10-Q filingAug 12, 2026
  2. Results of Operations and Financial Condition · Regulation FD DisclosureAug 12, 2026
  3. 10-Q filingMay 13, 2026
  4. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing · Other EventsMay 13, 2026
  5. Regulation FD Disclosure · Other EventsApr 15, 2026

Disclosure sections

Items 2.02, 7.01, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 2.02Item 2.02 - Results of Operations
Item 2.02. Results of Operations and Financial Condition. Reviva Pharmaceuticals Holdings, Inc. (the “Company”) issued a press release on May 13, 2026 disclosing financial information and operating metrics for its fiscal quarter ended March 31, 2026 and discussing its business outlook. A copy of the Company’s press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 7.01Item 7.01 - Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. See “Item 2.02 Results of Operations and Financial Condition” above. The information in this Current Report on Form 8-K under Items 2.02 and 7.01, including the information contained in Exhibit 99.1, is being furnished to the Securities and Exchange Commission, and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by a specific reference in such filing.

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.